Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders of pregnancy, gestational diabetes, have a preterm birth or cesarean ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

But virtual diabetes and weight management care changed when GLP-1 drug Wegovy was approved for weight loss in June 2021. As the drugs' popularity reached new heights, it became an expensive item ...

Can GLP-1 Meds Harm Your Eyes? By Ernie Mundell HealthDay Reporter MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss ...